Masto Peptide CS China Suppliers High Purity Weight Loss Peptide Factory
Product Overview
Masto peptide CS represents a breakthrough in metabolic regulation, utilizing a dual-action mechanism that synergizes GLP-1R and GCG-R pathways. By suppressing appetite and slowing gastric emptying while simultaneously accelerating fat breakdown and oxidation, it provides a comprehensive solution for weight management and visceral fat reduction.
Engineered for high efficacy, this pharmaceutical-grade peptide is primarily indicated for individuals with a BMI ≥ 28 kg/m², or those with a BMI ≥ 24 kg/m² struggling with metabolic complications such as hyperglycemia and fatty liver. It offers a sophisticated approach to glycemic control for type 2 diabetes patients, combining potency with a structured titration protocol for optimal safety.
Detailed Parameters
| Core Mechanisms | GLP-1R & GCG-R Synergism | Primary Indication | Weight Loss & Glycemic Control |
|---|---|---|---|
| Target BMI (General) | ≥ 28 kg/m² | Target BMI (Comorbid) | ≥ 24 kg/m² |
| Starting Dosage | 2 mg once weekly | Maintenance Dosage | 4 mg to 6 mg weekly |
| Administration | Subcutaneous Injection | Preferred Site | Abdomen, Upper Arm, or Thigh |
| Key Metric | Up to 14.84% Weight Loss | Clinical Effect | Reduced Visceral Fat & HbA1c |
Key Advantages
Dual-Target Synergy
Simultaneous appetite suppression and accelerated fat oxidation for maximum efficiency.
Weekly Administration
Once-weekly dosing schedule simplifies patient compliance and long-term management.
Superior HbA1c Lowering
Outperforms single-target drugs in managing blood glucose levels for type 2 diabetes.
Visceral Fat Reduction
Significantly reduces waist circumference and liver lipids to combat fatty liver disease.
Controlled Titration
Gradual dose escalation minimizes gastrointestinal side effects for better tolerance.
High Pure Grade
Manufactured under strict pharmaceutical standards to ensure purity and biological activity.
Product Gallery
Management Platforms
API Sourcing
Secure procurement of high-purity pharmaceutical intermediates and active peptides.
Quality Control
Rigorous HPLC and MS testing to ensure strict adherence to molecular specifications.
Compliance Monitoring
Ensuring all chemical raw materials meet international pharmaceutical safety standards.
Logistics Tracking
Cold-chain management for peptide stability during global transit.
Inventory Management
Real-time stock updates for popular chemicals and research-grade peptides.
Technical Support
Expert guidance on solubility, storage, and stability for API integration.
Investment Return Comparison
| Metric | Single-Target Peptide | Masto Peptide CS |
|---|---|---|
| Avg. Weight Loss | 5% - 10% | Up to 14.84% |
| Metabolic Impact | Glucose Reduction Only | Glucose + Lipid Oxidation |
| Visceral Fat Reduction | Moderate | Significant |
| Dosing Frequency | Daily/Weekly | Once Weekly |
| Glycemic Efficacy | Standard | Superior (HbA1c Focus) |
Frequently Asked Questions
Unlike standard agonists, Masto peptide CS combines GLP-1R for appetite suppression with GCG-R to accelerate fat breakdown, creating a dual effect of reducing intake and increasing calorie expenditure.
It is designed for adults with a BMI ≥ 28 kg/m², or those with BMI ≥ 24 kg/m² who have metabolic complications like hypertension, fatty liver, or type 2 diabetes.
The recommended protocol is starting at 2 mg weekly, increasing to 4 mg after 4 weeks, and finally to 6 mg after another 4 weeks to allow the body to adapt.
It is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Through the GCG-R mechanism, it helps reduce liver lipids and visceral fat, making it highly effective for managing fatty liver associated with metabolic syndrome.
Yes, it can be used as a monotherapy or in combination with oral hypoglycemic agents, though monitoring is required when used in combination therapy to prevent hypoglycemia.
Ready to Optimize Your Pharmaceutical Supply Chain?
Contact Us
